Given the relative ease by which this novel strategy can be implemented in routine clinical practice, the significant added value to the interpretation of immunophenotypically suspicious T-cell subsets and the potential cost savings, we believe that dual TRBC1/TRBC2 staining is likely to be adopted as a new laboratory standard in the clinical flow cytometric evaluation of leukemic T-cell neoplasms. This evidence concerns the gene TRBC2 and T-cell and NK-cell neoplasm.